Avantor/$AVTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avantor
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Ticker
$AVTR
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
13,500
ISIN
US05352A1007
Website
Avantor Metrics
BasicAdvanced
$9.1B
12.78
$1.04
1.09
-
Price and volume
Market cap
$9.1B
Beta
1.09
52-week high
$28.00
52-week low
$11.82
Average daily volume
12M
Financial strength
Current ratio
1.122
Quick ratio
0.694
Long term debt to equity
53.773
Total debt to equity
67.343
Interest coverage (TTM)
2.49%
Profitability
EBITDA (TTM)
1,114.2
Gross margin (TTM)
33.56%
Net profit margin (TTM)
10.70%
Operating margin (TTM)
10.60%
Effective tax rate (TTM)
16.69%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
3.53%
Return on equity (TTM)
12.52%
Valuation
Price to earnings (TTM)
12.782
Price to revenue (TTM)
1.353
Price to book
1.49
Price to tangible book (TTM)
-3.19
Price to free cash flow (TTM)
13.568
Free cash flow yield (TTM)
7.37%
Free cash flow per share (TTM)
97.95%
Growth
Revenue change (TTM)
-2.64%
Earnings per share change (TTM)
173.61%
3-year revenue growth (CAGR)
-3.98%
3-year earnings per share growth (CAGR)
5.41%
What the Analysts think about Avantor
Analyst ratings (Buy, Hold, Sell) for Avantor stock.
Bulls say / Bears say
Avantor's strategic divestiture of its clinical services business for approximately $650 million is expected to strengthen its balance sheet and reduce interest expenses, allowing the company to focus on growth in its lab and production businesses. (stocktitan.net)
The company has raised its cost savings target to $400 million by 2027, indicating a strong commitment to improving operational efficiency and profitability. (finviz.com)
Avantor's NuSil brand received the 2024 North American Daily Kaizen Management award, recognizing its commitment to operational excellence and continuous improvement, which could enhance its competitive position. (stocktitan.net)
Avantor reported a 6% decline in first-quarter net sales to $1.58 billion, missing estimates and reflecting reduced government spending impacting its laboratory solutions sales. (gurufocus.com)
The resignation of CEO Michael Stubblefield, who led the company since 2014, introduces leadership uncertainty during a period of underperformance. (gurufocus.com)
Barclays has lowered Avantor's price target from $23 to $18, citing concerns over potential pharmaceutical-specific tariffs and their impact on the industry. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Avantor Financial Performance
Revenues and expenses
Avantor Earnings Performance
Company profitability
Avantor News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avantor stock?
Avantor (AVTR) has a market cap of $9.1B as of June 20, 2025.
What is the P/E ratio for Avantor stock?
The price to earnings (P/E) ratio for Avantor (AVTR) stock is 12.78 as of June 20, 2025.
Does Avantor stock pay dividends?
No, Avantor (AVTR) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Avantor dividend payment date?
Avantor (AVTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Avantor?
Avantor (AVTR) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.